long stress-induced non-coding transcript 5Genealiases: []
Q-omics provides the consensus-scored LSINCT5 profile across patient tissues and cancer cell-line models. LSINCT5 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LSINCT5 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, LSINCT5 RNA expression shows 9,416 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, KIRC, and THYM as cancer lineages where LSINCT5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LSINCT5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LSINCT5 survival associations across molecular data types. LSINCT5 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LSINCT5 RNA expression–survival associations across cancer types. High LSINCT5 expression shows unfavorable associations in LIHC, LUSC and ACC, but favorable associations in LUAD, HNSC and THYM. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LSINCT5 RNA expression.
This table summarizes LSINCT5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LSINCT5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LSINCT5 shows lower tumor expression in KIRC, LUAD, LUSC, BRCA, KICH and KIRP. The KIRC box plot shows higher LSINCT5 RNA expression in normal versus tumor tissue (log2 FC = −0.044, t-test p < 0.001).
This table shows molecular features associated with LSINCT5 in patient tissues and cancer cell lines. In patient samples, LSINCT5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
